Alector (ALEC) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed Alector (ALEC) over the past year, losing 31.4% versus a loss of 37.5%. Over five years, ALEC leads with a -91.8% price change compared with -94.8% for RNAC. Alector is the larger company by market cap ($220.5 million vs $204.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | RNAC |
|---|---|---|
| Share price | $1.98 | $6.76 |
| Market cap | $220.52M | $204.53M |
| 1-day change | +2.86% | +1.20% |
| YTD return | +23.08% | -7.35% |
| 1-year return | -37.46% | -31.42% |
| 5-year return | -91.76% | -94.79% |
| EPS (TTM) | $-1.09 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $11.00 |
| 52-week low | $1.09 | $5.60 |
| Distance from 52-week high | -41.91% | -38.55% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +67.09% | +398.08% |
| Average volume | 2.77M | 131.99K |
| Shares outstanding | 111.66M | 30.26M |
| Employees | 103 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ALEC vs RNAC FAQ
Which is bigger, Alector or Cartesian Therapeutics?
Alector (ALEC) is larger, with a market capitalization of $220.52M compared with $204.53M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, ALEC or RNAC?
RNAC returned -31.42% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Cartesian Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for Cartesian Therapeutics.